|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunostaining indicated that SHH expression was present in 60% of PJPs, 72% of adenomas, and 84% of carcinomas, whereas 68% of PJPs, 72% of adenomas, and 88% of carcinomas exhibited cytoplasmic expression of PTCH.
|
26997450 |
2016 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The moderate overexpression of TGF-β1 and TβRII mRNA in PTC tissues (61.5% and 62.5%, respectively), counteracted their high overexpression in FTC tissues (100% and 100%, respectively), while EGFR overexpression was similar in both carcinomas.
|
24973511 |
2014 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
EGFR-H was detected in 39.5% of carcinomas (n = 32) from patients with papillary (PTC, 46.2%, n = 18), follicular (29.6%, n = 8), and anaplastic (100.0%, n = 6) but not medullary (0.0%, n = 9) thyroid carcinoma.
|
23746767 |
2013 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas.
|
22803838 |
2012 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To determine whether alterations in the PTCH1 gene are responsible for this pathway activation, we screened pancreatic carcinomas for mutations in PTCH.
|
22076568 |
2012 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The molecular pathology of thyroid cancer is now better understood because of our ability to identify RET/PTC rearrangements and BRAF mutations in the aetiopathogenesis of the large majority of PTCs and the high prevalence of RAS mutations and PAX8/PPARgamma rearrangements in follicular patterned carcinomas (FTCs and follicular variant of PTCs).
|
19147628 |
2009 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry analysis showed that Skp2 was overexpressed significantly in thyroid carcinomas (26 out of 51) compared with goitres (0 out of 12, P<0.001) or adenomas (1 out of 10, P<0.05), and that high Skp2 expression was detected more often in anaplastic thyroid (ATC; 83%, n=12) than follicular thyroid (FTC; 40%, n=20) or papillary thyroid (PTC; 42%, n=19) carcinomas (P<0.05).
|
17639054 |
2007 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Correlations were found in normal tissue specimens between the expression of TAp73 and DeltaNp73 transcripts and that of p53, p14ARF p16INK4a, but these correlations were lost in carcinomas (PTC or FTC).
|
16290057 |
2006 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Ret/PTC 1, the predominant rearrangement, was more prevalent in nonirradiated compared with irradiated carcinomas (66.7 vs. 27.0%; P = 0.04).
|
15126554 |
2004 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Employing in situ hybridization to detect INSL-3 transcripts and specific rabbit antisera against the INSL-3 proteins, both INSL-3 isoforms were detected in patients with Graves' disease (n=10), follicular carcinomas (FTC; n=12), papillary carcinomas (PTC; n=9) and undifferentiated anaplastic carcinomas (UTC; n=15).
|
12684664 |
2003 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A strong correlation was observed between the solid-follicular subtype of papillary carcinoma and the RET/PTC3 isoform: 19 of the 24 RET/PTC-positive solid-follicular carcinomas harbored a RET/PTC3 rearrangement, whereas only 5 had a RET/PTC1 rearrangement.
|
10566678 |
1999 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results show that ret/PTC1-induced thyroid follicular cell carcinomas retain TSH responsiveness and maintain a benign biologic behavior despite histologic evidence of anaplasia.
|
9121114 |
1997 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
No PTCH gene mutations were detected in 10 primary colon carcinomas and eighteen bladder carcinomas.
|
9192811 |
1997 |